ASP Isotopes
ASP Isotopes' revenue rose 475.5% to $24 million in fiscal 2025. Its operating margin was −251.2%, up from −636.0% a year earlier. Free cash flow was −$47 million. The diluted share count rose 49.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What ASP Isotopes does
ASP Isotopes is developing technology to separate and enrich isotopes, which are forms of an element with different weights. The materials are used in nuclear medicine, advanced semiconductors and nuclear energy. It uses two proprietary methods: the Aerodynamic Separation Process and a laser-based Quantum Enrichment technology.
Its first products are enriched Carbon-14, Silicon-28 and Ytterbium-176. The company says Carbon-14 could go into new drugs and agricultural chemicals, Silicon-28 into advanced semiconductors and quantum computing, and Ytterbium-176 into radiotherapy for cancer. It began commercial production at two enrichment plants in Pretoria, South Africa, in the first half of 2025, and is targeting its first commercial shipments in 2026. It says it has no sales of enriched isotopes yet and expects to depend on a few large customers.
In January 2026 it acquired Renergen, a South African company that explores for natural gas onshore and produces liquid helium and liquefied natural gas. At the end of 2025 ASP Isotopes had 271 full-time employees, 189 of them in South Africa.
Its biggest risks, as it describes them
- A very short operating history and continuing losses, and it may never generate significant revenue.
- Its future depends on end markets such as medical imaging, and on its ability to introduce its isotopes successfully.
- No sales of enriched isotopes yet, and likely dependence on a few large customers.
- It may not realize the expected benefits of acquisitions, including Renergen.
- Risks tied to expanding the Virginia Gas Project and to needing more capital.
Income statement
ASP Isotopes lost money in fiscal 2025: a net loss of $160 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | 2 | 8 | 62 | 333 |
| Debt incl. finance leases | — | 1 | 3 | 15 |
| Net debt (negative means net cash) | — | −7 | −59 | −318 |
| Net debt to EBITDA | — | — | — | — |
| Debt to equity | — | 0.1x | 0.1x | 0.1x |
| Interest coverage | — | −135.3x | −101.8x | −104.2x |
| Current ratio | 1.7x | 1.9x | 9.3x | 12.2x |
| Quick ratio | 1.7x | 1.9x | 9.3x | 12.2x |
Cash flow
Projections
Project ASP Isotopes' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $21,600 of ASP Isotopes shares on the open market, and 7 insiders sold $9.4 million, $7.5 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 28, 2026 | Robert John Andrew RyanDirector | Bought | 8,000 | $2.70 | $21,600 | Form 4 |
| Sep 8, 2026 | Robert AinscowCOO | Sold plan | 8,438 | $4.29 | $36,199 | Form 4 |
| Sep 4, 2026 | Paul Elliot MannChairman and CEO, Director | Sold plan | 83,759 | $4.10 | $343,412 | Form 4 |
| Sep 3, 2026 | Paul Elliot MannChairman and CEO, Director | Sold plan | 83,758 | $3.92 | $328,331 | Form 4 |
| Sep 2, 2026 | Paul Elliot MannChairman and CEO, Director | Sold plan | 83,758 | $3.91 | $327,494 | Form 4 |
| Sep 2, 2026 | Robert AinscowCOO | Sold plan | 25,000 | $3.91 | $97,750 | Form 4 |
| Sep 2, 2026 | Donald George AinscowEVP, Gen Counsel, Secretary | Sold | 23,678 | $3.89 | $92,107 | Form 4 |
| Jul 1, 2026 | Heather KiesslingChief Financial Officer | Sold plan | 23,124 | $6.28 | $145,219 | Form 4 |
| Jun 30, 2026 | Donald George AinscowEVP, Gen Counsel, Secretary | Sold | 100,000 | $6.14 | $614,000 | Form 4 |
| Jun 30, 2026 | Todd WiderDirector | Sold | 50,000 | $6.12 | $306,000 | Form 4 |
| Jun 30, 2026 | Michael GorleyDirector | Sold | 30,000 | $6.27 | $188,100 | Form 4 |
| Jun 29, 2026 | Todd WiderDirector | Sold | 50,000 | $6.25 | $312,500 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | 5 of 9 | 3 of 9 |
| Rule of 40 | — | 220.6% | 276.6% |
| Altman Z'' | −3.31 | 1.51 | 3.69 |
| Accruals ratio | −54.4% | −25.8% | −41.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | — | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | Fail | Fail |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | Pass | Fail |
| Revenue rose relative to assets | — | Pass | Pass |
| F-score | — | 5 of 9 | 3 of 9 |
Compare
Put ASP Isotopes side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| ASP Isotopes | FY25 | 475.5% | −251.2% | −198.9% | — | — | 3 | |
| Flotek Industries | FY25 | 26.9% | 9.8% | — | 18.1% | 1.4x | 5 | Compare |
| Orion | FY25 | −3.8% | 1.5% | 3.0% | 1.3% | 8.1x | 3 | Compare |
| Ashland Global | FY25 | −13.7% | −42.5% | 2.0% | −17.5% | — | 5 | Compare |
| Cabot | FY25 | −7.0% | 16.7% | 10.5% | 15.9% | 1.1x | 6 | Compare |
4 years of figures
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 0 | 0 | 4 | 24 |
| Revenue growth | — | — | 857.0% | 475.5% |
| Gross profit | 0 | 0 | 2 | 3 |
| Research and development | 1 | 1 | 3 | 12 |
| Operating income | −5 | −16 | −26 | −60 |
| Net income | −5 | −16 | −32 | −160 |
| Diluted EPS (US$) | — | −0.49 | −0.63 | −2.11 |
| Diluted shares (millions) | 27 | 33 | 56 | 83 |
| Cash flow | ||||
| Cash from operations | −3 | −5 | −17 | −38 |
| Capital expenditure | 4 | 2 | 10 | 10 |
| Free cash flow | −7 | −8 | −26 | −47 |
| Dividends paid | 0 | 0 | 3 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 9 | 9 | 16 |
| Balance sheet at fiscal year end | ||||
| Cash and short-term investments | 2 | 8 | 62 | 333 |
| Debt incl. finance leases | — | 1 | 3 | 15 |
| Total assets | 12 | 28 | 94 | 498 |
| Total liabilities | 3 | 9 | 43 | 235 |
| Shareholders' equity | 10 | 16 | 48 | 204 |
| Margins and ratios | ||||
| Gross margin | — | 32.1% | 38.6% | 14.3% |
| Operating margin | — | −3,704.6% | −636.0% | −251.2% |
| Net margin | — | −3,762.8% | −782.4% | −670.2% |
| Free cash flow margin | — | −1,788.3% | −636.4% | −198.9% |
| Rule of 40 (growth + FCF margin) | — | — | 220.6% | 276.6% |
| Return on capital | — | — | — | — |
| Return on equity | — | −124.8% | −101.0% | −126.8% |
| Return on assets | — | −81.4% | −53.2% | −54.0% |
| Net debt to EBITDA | — | — | — | — |